(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
...
Ovid Therapeutics (OVID) said Tuesday that entered into a strategic partnership with Healx, which secured from the biopharmaceutical company an exclusive...
Ovid Therapeutics (OVID) said Monday it has obtained an exclusive license to AstraZeneca's (AZN) experimental epilepsy drug OV350 and other early-stage...
| Address | 1460 Broadway New York, New York 10036 |
| Phone | +1.646.661.7661 |
| Number of Employees | 55 |
| Recent SEC Filing | 08/09/2022 8-K |
| Chairman, President & Chief Executive Officer | Jeremy Max Levin |
| Chief Operating Officer | Jason Tardio |
| Chief Financial & Business Officer | Jeffrey A. Rona |
| Head-Research & Development | Claude Nicaise |
| Price Open | $2.20 |
| Previous Close | $2.18 |
| 52 Week Range | $1.65 - 4.20 |
| Market Capitalization | $154.9 M |
| Shares Outstanding | 70.4 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major | Next Earnings Announcement | 11/09/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$1.00 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | -4,734.49% |
| Return on Equity | -36.57% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
